Insider Trading History of Frykman Edward W

The following table details the insider trading activities (stock purchases, stock sales, and stock option exercises) by Frykman Edward W since 2008. The trader's CIK number is 1078202. At the time of the last reporting, Frykman Edward W was the Director of Arrowhead Pharmaceuticals, Inc.. (stock ticker symbol ARWR). Also see all insider trading activities at Arrowhead Pharmaceuticals, Inc..

Note that in the past FRYKMAN EDWARD W also reported insider trading activities as an insider of the following companies:

Yearly summary of insider trading at Acacia Research Corp (ACTG) by Frykman Edward W

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2010 ACTG 0 $0 77,400 $2,282,498 77,400 $553,684
2008 ACTG 0 $0 0 $0 5,000 $10,950

Yearly summary of insider trading at Arrowhead Pharmaceuticals, Inc. (ARWR) by Frykman Edward W

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2014 ARWR 0 $0 3,148 $50,295 5,000 $50,000


Insider trading activities at 2 companies by Frykman Edward W:

1. Acacia Research Corp (ACTG)

2. Arrowhead Pharmaceuticals, Inc. (ARWR)

Table 1. Insider trading of Acacia Research Corp (ACTG) by Frykman Edward W

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2010-12-08 ACTG Sale 27,400 29.27 801,998
2010-12-08 ACTG Option Ex 27,400 10.16 278,384
2010-12-07 ACTG Sale 50,000 29.61 1,480,500
2010-12-07 ACTG Option Ex 50,000 5.51 275,300
2008-02-12 ACTG Option Ex 5,000 2.19 10,950

Table 2. Insider trading of Arrowhead Pharmaceuticals, Inc. (ARWR) by Frykman Edward W

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2014-02-07 ARWR Sale 3,148 15.98 50,295
2014-02-07 ARWR Option Ex 5,000 10.00 50,000

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Frykman Edward W (Director of Arrowhead Pharmaceuticals, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.



©2023, insider-monitor.com. All rights reserved.